OMER Omeros Corporation
$17.49▲ +7.37%
Healthcare
Other
After hours
$17.49▲ +0.00%
Oct 27, 4:17 PM ET
Volume 894.4K
Avg Volume (10D) 1.18M
Key Metrics & Fundamentals
Market Cap
$1.27B
P/E Ratio
14.3
Div Yield
0.00%
52W Range
6.24 - 21.24
% vs 50 MA
-5.46%
% vs 200 MA
30.49%
RSI-14
48.1
MACD Histogram
-0.2000
Beta (1Y vs SPY)
1.75
Free Cash Flow
$4.10M
Gross Rev
$28.53M
Gross Profit
$27.73M
EBITDA
$4.89M
COGS
$798,000
Operating Exp
$27.66M
Operating Income
$74,000
EBIT
$74,000
Pretax Income
$6.67M
Net Income
$13.23M
EPS (Diluted)
0.15
Price & Volume History
Loading chart…
Recent News
Sector Update: Healthcare Stocks Softer Late Afternoon
MT Newswires · Oct 16, 2026 3:56 PM ET
Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16
Stocktwits · Oct 16, 2026 3:24 PM ET
Update: Omeros Shares Fall After Narsoplimab Application Rejected Again by EU Agency
MT Newswires · Oct 16, 2026 2:25 PM ET
Sector Update: Healthcare Stocks Mixed Friday Afternoon
MT Newswires · Oct 16, 2026 1:44 PM ET
Sector Update: Healthcare Stocks Edge Higher Premarket Friday
MT Newswires · Oct 16, 2026 9:11 AM ET
Omeros Shares Fall 4% as European Regulators Uphold Negative Opinion on Narsoplimab
InvestorsHub · Oct 16, 2026 8:40 AM ET
Omeros shares slide following European regulatory setback for Narsoplimab
Investing.com · Oct 16, 2026 8:06 AM ET
Omeros Faces Second Rejection Of Narsoplimab In Europe – OMER Stock Falls Below Key Support For First Time In Nearly 3 Months
Stocktwits · Oct 16, 2026 8:00 AM ET
Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA
Business Wire · Oct 16, 2026 6:19 AM ET
Dow Jones Futures Fall After Nasdaq Hits New High; Sandisk, Micron Trigger Buy Signals
Investor's Business Daily · Sep 23, 2026 8:05 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See OMER's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.